Sun Pharmaceutical Industries
Sun Pharmaceutical Industries
Shareholder Return: 3-year average, Sales Growth: 3-year Compounded Annual Growth Rate, Return On Equity: 3-year Return on Equity.
At a Glance
-
Shareholder Return262%
-
Sales Growth51%
-
Return on Equity20 %
Why Super 50
With revenues of $4.5 billion, it is India's largest pharmaceutical company and the fifth largest generic pharmaceutical manufacturer in the world. It is also the fastest growing pharmaceutical company in the country and a large part of its growth has come through acquisitions. Sun recently completed a $3.2 billion-acquisition of rival Ranbaxy Laboratories and announced that it is open to making more such large acquisitions.
